NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose...

Related Keywords

Miami ,Florida ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Alexander Prezioso ,Marshall Woodworth ,Jamesp Tursi ,Development Rd Expenses ,Neurobo Pharmaceuticals Inc Nasdaq ,Fund The Company Into Fourth Quarter ,Nasdaq ,Donga St Co ,Governance Committee ,Drug Administration ,Neurobo Pharmaceuticals ,Neurobo Pharmaceuticals Inc ,Safety Review Committee ,Received First Site Institutional Review Board ,Proceed With ,Dose First Patient ,Second Quarter ,Approval Recommending That ,Two Part Phase ,Second Half ,Company Into ,Fourth Quarter ,Hyung Heon Kim ,Chief Executive Officer ,G Protein Coupled Receptor ,Investigational New Drug ,Institutional Review Board ,Chief Financial ,Chief Financial Officer ,Acting Chief Financial ,Clinical Pharmacology ,Appointed James ,Administrative Expenses ,Operating Expenses ,Metabolic Dysfunction Associated Steatohepatitis ,Private Securities Litigation Reform Act ,Consolidated Statements ,Ended December ,Nc ,